[{"address1": "3020 Carrington Mill Blvd.", "address2": "Suite 475", "city": "Morrisville", "state": "NC", "zip": "27560", "country": "United States", "phone": "212 554 4484", "fax": "212 554 4531", "website": "https://www.tgtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.", "fullTimeEmployees": 338, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael S. Weiss Esq.", "age": 58, "title": "Chairman, CEO & President", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1968759, "exercisedValue": 0, "unexercisedValue": 5090000}, {"maxAge": 1, "name": "Mr. Sean A. Power CPA", "age": 42, "title": "CFO, Corporate Secretary & Treasurer", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 670578, "exercisedValue": 0, "unexercisedValue": 3031375}, {"maxAge": 1, "name": "Ms. Jenna  Bosco", "title": "Senior Vice President of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Waldman", "title": "Chief Commercialization Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 3, "overallRisk": 10, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 35.98, "open": 36.1433, "dayLow": 35.29, "dayHigh": 36.785, "regularMarketPreviousClose": 35.98, "regularMarketOpen": 36.1433, "regularMarketDayLow": 35.29, "regularMarketDayHigh": 36.785, "payoutRatio": 0.0, "beta": 2.136, "trailingPE": 244.73332, "forwardPE": 37.84536, "volume": 2009219, "regularMarketVolume": 2009219, "averageVolume": 2754565, "averageVolume10days": 3479200, "averageDailyVolume10Day": 3479200, "bid": 31.29, "ask": 41.54, "bidSize": 1, "askSize": 1, "marketCap": 5766076416, "fiftyTwoWeekLow": 12.93, "fiftyTwoWeekHigh": 43.32, "priceToSalesTrailing12Months": 17.525854, "fiftyDayAverage": 35.6396, "twoHundredDayAverage": 28.211824, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 5274662912, "profitMargins": 0.07107, "floatShares": 134539735, "sharesOutstanding": 157071008, "sharesShort": 24892921, "sharesShortPriorMonth": 25952803, "sharesShortPreviousMonthDate": 1740700800, "dateShortInterest": 1743379200, "sharesPercentSharesOut": 0.1585, "heldPercentInsiders": 0.093789995, "heldPercentInstitutions": 0.62765, "shortRatio": 7.03, "shortPercentOfFloat": 0.1749, "impliedSharesOutstanding": 157071008, "bookValue": 1.544, "priceToBook": 23.775906, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": 23383000, "trailingEps": 0.15, "forwardEps": 0.97, "lastSplitFactor": "100:5625", "lastSplitDate": 1335744000, "enterpriseToRevenue": 16.032, "enterpriseToEbitda": 125.596, "52WeekChange": 1.6090975, "SandP52WeekChange": 0.059571505, "quoteType": "EQUITY", "currentPrice": 36.71, "targetHighPrice": 55.0, "targetLowPrice": 11.0, "targetMeanPrice": 43.0, "targetMedianPrice": 48.0, "recommendationMean": 1.625, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 311000000, "totalCashPerShare": 2.141, "ebitda": 41997000, "totalDebt": 254380000, "quickRatio": 4.854, "currentRatio": 6.246, "totalRevenue": 329004000, "debtToEquity": 114.398, "revenuePerShare": 2.264, "returnOnAssets": 0.05777, "returnOnEquity": 0.122150004, "grossProfits": 290518016, "freeCashflow": -62020876, "operatingCashflow": -40517000, "revenueGrowth": 1.46, "grossMargins": 0.88302004, "ebitdaMargins": 0.12765001, "operatingMargins": 0.27683002, "financialCurrency": "USD", "symbol": "TGTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "TG Therapeutics, Inc.", "longName": "TG Therapeutics, Inc.", "fiftyTwoWeekHighChangePercent": -0.15258543, "fiftyTwoWeekChangePercent": 160.90974, "earningsTimestamp": 1736861400, "earningsTimestampStart": 1745929800, "earningsTimestampEnd": 1746448200, "earningsCallTimestampStart": 1741008600, "earningsCallTimestampEnd": 1741008600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 0.15, "epsForward": 0.97, "epsCurrentYear": 1.05, "priceEpsCurrentYear": 34.961906, "fiftyDayAverageChange": 1.0704002, "fiftyDayAverageChangePercent": 0.030034015, "twoHundredDayAverageChange": 8.498175, "twoHundredDayAverageChangePercent": 0.3012274, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1744415896, "regularMarketTime": 1744401601, "exchange": "NCM", "messageBoardId": "finmb_143627354", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.0289037, "regularMarketPrice": 36.71, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1272893400000, "postMarketChangePercent": -0.572049, "postMarketPrice": 36.5, "postMarketChange": -0.209999, "regularMarketChange": 0.72999954, "regularMarketDayRange": "35.29 - 36.785", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 2754565, "fiftyTwoWeekLowChange": 23.779999, "fiftyTwoWeekLowChangePercent": 1.8391336, "fiftyTwoWeekRange": "12.93 - 43.32", "fiftyTwoWeekHighChange": -6.6100006, "displayName": "TG Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-04-12"}]